Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.

Detailed Description
-----------------
Sections of the tumor tissue will be HE stained. Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry. Immunohistochemical staining against cytokeratin which colors cancer cells will be made to assist the observer in the evaluation of uPAR microexpression pattern. A semiqualitative scale corresponding to the level of uPAR expression will be made. Quantitative polymerase chain reaction will be used to validate the immunohistochemistry uPAR expression pattern. An electronic scoring system (digital pathology) will be trained to access the expression of uPAR in both tumor- and normal tissue.

Official Title
-----------------
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas

Conditions
-----------------
Esophagus Cancer, Adenocarcinoma

Intervention / Treatment
-----------------
* Other: uPAR immunohistochemistry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years old. Patients who underwent curatively intended surgery for gastroesophageal cancer Patients who underwent surgery after 01-01-2016. Exclusion Criteria: Patients who applied for an exception from medical research at the National Registry of Tissue Use. Patients with other histological subtypes than adenocarcinoma.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Interventional Model Description: The patients will be drawn from the existing clinical biobank. The biobank is located at the department of pathology, Rigshospitalet. From this clinical biobank, a new temporary research biobank will be made. Supplementary sections from formalin-fixed paraffin embedded (FFPE) blocks containing tumor tissue will be cut and Haematoxylin and eosin (HE) and immunohistochemical (IHC) staining will be performed.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: uPAR expression<br>Immunohistochemistry | Other: uPAR immunohistochemistry<br>* Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| uPAR microexpression | Our primary objective is to investigate uPAR microexpression in gastroesophageal adenocarcinomas both qualitatively and semi-quantitatively. This will be done by a pathology analysis of gastroesophageal cancer resections. | Up to 6 months | 
| Tumor-to-background ratio | A pathology staining will determine the uPAR in the tumor compared with the healthy cells. | Up to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| uPAR in patient groups | Baseline statistical analysis of patient groups and their expression of uPAR in their resected tumor tissues will be made. | Up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
urokinase plasminogen activator receptor, uPAR, Cardia, Adenocarcinoma, Immunohistochemistry